Viking Therapeutics (VKTX) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[2], including 2 Phase 3[1].
Trial NCT07104500[3] evaluates VK2735 in Weight Loss with a target enrollment of 4500 participants. Trial NCT07104383[4] evaluates VK2735 in Weight Loss with a target enrollment of 1100 participants.
No Form 4 insider filings for VKTX were recorded at the SEC in the past 30 days[5].